Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results

• Váldodahkkit: Yutaka Osuga (Dahkki), Yoshifumi Seki (Dahkki), Masataka Tanimoto (Dahkki), Takeru Kusumoto (Dahkki), Kentarou Kudou (Dahkki), Naoki Terakawa (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: BMC, 2021-06-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract Background Relugolix is a once-daily, oral, nonpeptide, gonadotropin-releasing hormone receptor antagonist. The aim of this study was to evaluate safety of relugolix over 24 weeks in women with endometriosis-associated pain. Methods This phase 2, randomized, open-label, parallel-group exten...